$45.76
+0.99 (+2.21%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ATRC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
27 interventional · 5 observational · 12 with posted results
Held by 14 tracked-famous managers (MARSHALL WACE, LLP, Point72 Asset Management, L.P., Qube Research & Technologies Ltd, AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, +9 more) · FINRA short interest 3.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Tracking Results of Ablations to Combat AF Registry Generation 2NCT05111015observationalPatient's AF burden 6-month after receiving the ablation procedure | — | Recruiting | Device: Open Concomitant Surgical Ablation Procedures, Hybrid (Convergent) Ablation Procedures, AtriCure Hybrid Totally Thoracoscopic Ablation Procedures, AtriCure LAA Exclusion Procedures | Atrial Fibrillation | 10,000 | Jan 2040 | ≤ 4,913 d | 2026-06-29 |
| Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb PainNCT06908538observationalPrimary Outcome Measure | — | Recruiting | Device: cryoablation | Amputation, Amputation of Lower Limb, Amputation of Upper Limb, Amputation, Limb Loss, Amputation, Traumatic/Surgery, Cryo Analgesia | 2,000 | Apr 2035 | ≤ 3,176 d | 2026-06-26 |
| A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal NervesNCT05110989observationalEfficacy of cryo nerve block to generate cryoanalgesia as post operative pain management | — | Recruiting | Device: AtriCure Cryo Nerve Block (cryoNB) Device Family | Post Operative Pain | 5,000 | Jan 2035 | ≤ 3,087 d | 2026-06-29 |
| Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction TrialNCT05478304Primary Effectiveness EndpointRandomized · Triple-masked · Treatment | Not applicable | Active, not recruiting | Device: AtriClip LAA Exclusion System | Ischemic Stroke, Systemic Embolism | 6,573 | Dec 2031 | ≤ 1,960 d | 2026-03-24 |
| HEAL-IST IDE TrialNCT05280093Primary Effectiveness EndpointOpen-label · Treatment | Not applicable | Active, not recruiting | Device: AtriCure ISOLATOR Synergy Surgical Ablation System | Inappropriate Sinus Tachycardia | 142 | Feb 2027 | ≤ 193 d | 2026-03-02 |
| BoxX-NoAF Clinical TrialNCT06989775Primary Effectiveness EndpointRandomized · Triple-masked · Prevention | Not applicable | Recruiting | Device: Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System | Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative | 960 | Feb 2027 | ≤ 193 d | 2026-06-29 |
| Inappropriate Sinus Tachycardia RegistryNCT05107635observationalAtriCure commercially available devices used to treat IST or POTS | — | Recruiting | Device: AtriCure Commercially Available Devices | Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome | 500 | Jan 2027 | ≤ 165 d | 2026-06-26 |
| CONVERGE Post-Approval Study (PAS)NCT05393180Freedom from AF/AFL/AT >30 seconds through 12 months absent new or increased dose of class I/III AAD.Open-label · Treatment | Not applicable | Active, not recruiting | Device: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF | Chronic Atrial Fibrillation | 53 | 2027-01-01 | in 135 d | 2026-04-22 |
| AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation TreatmentNCT03732794Primary Effectiveness Endpoint: Freedom from AF/Atrial Flutter (AFL)/Atrial Tachycardia (AT)Open-label · Treatment | Not applicable | Active, not recruiting | Device: AtriCure CryoICE & AtriClip LAA Exclusion | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 150 | 2024-06-27actual | — | 2024-10-15 |
| CONVERGE CAP Study-For The Treatment Of Symptomatic Persistent or Long-standing Persistent AFNCT04239534Primary Effectiveness Endpoint- Freedom from Atrial Fibrillation, Atrial Tachycardia and Atrial FlutterOpen-label · Treatment | Not applicable | Withdrawnsponsor's stated reason: Start-up and enrolling activities have been suspended and study closed | Device: Convergence Of Epicardial And Endocardial RF Ablation | Atrial Fibrillation | 0 | Dec 2023 | — | 2022-07-27 |
| aMAZE Trial Continued Access ProtocolNCT04468334Freedom from episodes of atrial fibrillation > 30 seconds at 12 months post index pulmonary vein isolationOpen-label · Treatment | Not applicable | Completed | Device: LARIAT + PVI | Atrial Fibrillation | 82 | 2023-04-24actual | — | 2024-03-12 |
| FREEZE-AFIB Post-Market StudyNCT05089877results2025-01-13observationalFreedom From Death, Stroke (Regardless of Level of Disability), Myocardial Infarction, and Major Bleeding Events.Study Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: Surgical Ablation | Atrial Fibrillation, Atrial Flutter | 39 | 2023-03-31actual | — | 2025-01-13 |
| VCLIP Post-Market Study, Long-term Follow-up on LAA Exclusion Using AtriClipNCT05101993results2025-06-24Primary Performance EndpointOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: AtriClip | Left Atrial Appendage Absent | 156 | 2023-03-31actual | — | 2025-07-03 |
| Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial FibrillationNCT02695277Number of subjects free from documented Atrial Fibrillation (AF), Atrial Flutter (AFL) or Atrial Tachycardia (AT) episodes > 30 seconds in duration through 12 months follow-up, in the absence of Class I or III Antiarrhythmic Drugs (AADs).Randomized · Open-label · Treatment | Not applicable | Completed | Device: AtriCure Bipolar System, Standard Endocardial Ablation with Catheter, AtriClip® PRO LAA Exclusion System, Endocardial Ablation with Catheter, Repeated Endocardial ablation(s) | Atrial Fibrillation, Persistent and Longstanding Persistent Atrial Fibrillation | 146 | Nov 2022actual | — | 2024-10-15 |
| Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) ApproachNCT02393885results2024-12-19Primary Effectiveness EndpointOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation | Atrial Fibrillation, Persistent or Longstanding Persistent Atrial Fibrillation | 90 | 2022-03-28actual | — | 2024-12-19 |
| aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial FibrillationNCT02513797Freedom from episodes of atrial fibrillation > 30 seconds at 12 months post index pulmonary vein isolationRandomized · Open-label · Treatment | Not applicable | Unknown status | Device: LARIAT + PVI, Pulmonary Vein Isolation | Atrial Fibrillation | 600 | 2021-04-21actual | — | 2021-09-05 |
| CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)NCT01984346results2022-02-10Primary Efficacy Endpoint - Number of Participants to Achieve Freedom From AF/AT/AFL.Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax, Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering | Persistent Atrial Fibrillation | 170 | Aug 2019actual | — | 2023-11-13 |
| AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)NCT02701062results2021-11-24Number of Perioperative Complications Associated With AtriClip PlacementRandomized · Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Device: AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems · Drug: Anticoagulation Therapy | Post-Operative Atrial Fibrillation | 562 | 2019-04-26actual | — | 2021-11-24 |
| The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)NCT02922153results2020-09-04Primary Outcome 1: Forced Expiratory Volume (FEV1) at 48-Hours Post-SurgeryRandomized · Double-masked · TreatmentInformed Consent Form ↗ · Study Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Cryoanalgesia · Drug: Standard of Care | Pain | 84 | 2019-03-04actual | — | 2020-09-04 |
| ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial FibrillationNCT01694563results2019-09-13The Number of Participants Free From Atrial Fibrillation (AF), Atrial Flutter or Atrial Tachycardia While Off Class I and Class III Antiarrhythmic Drugs for at Least 4 Weeks.Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Synergy Ablation System | Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 365 | 2017-10-23actual | — | 2019-10-09 |
| Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)NCT01661205results2017-05-17Number of Patients With Pre-specified Safety Endpoints Occurring in the First 30 Days Post-index Procedure or Hospital Discharge, Whichever is Longer.Open-label · Treatment | Not applicable | Completed | Device: Ablation procedure staged catheter ablation | Atrial Fibrillation | 30 | Dec 2015actual | — | 2017-05-17 |
| Stroke Feasibility StudyNCT01997905results2016-10-21Number of Serious Adverse Events Within 30 Days Post-Index ProcedureOpen-label · Treatment | Phase 1/2 | Completed | Device: AtriClip LAA Exclusion Device | Atrial Fibrillation, AFib | 13 | Jul 2015actual | — | 2016-12-14 |
| LARIAT RS: An Observational Study of the Performance and Safety of the LARIAT RSNCT02059707Percent of subjects with complete exclusionOpen-label · Basic science | Not applicable | Completed | Device: LARIAT RS Suture Delivery Device | Atrial Appendage | 58 | Dec 2014actual | — | 2020-01-09 |
| Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) StudyNCT01246466results2021-04-01Primary Safety EndpointOpen-label · Treatment | Not applicable | Completed | Device: Hybrid: AtriCure Bipolar System & EP ablation procedure | Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 24 | Dec 2012actual | — | 2021-04-01 |
| Left Atrial Appendage Exclusion StudyNCT01983605Rate of device related serious adverse eventsOpen-label · Basic science | Not applicable | Completed | Device: LARIAT Suture Delivery Device | Atrial Appendage | 96 | Mar 2011actual | — | 2020-01-09 |
| Safety and Effectiveness of Left Atrial Appendage OcclusionNCT00567515Safety - Device related complicationsOpen-label · Treatment | Phase 2 | Completed | Device: AtriCure LAA Exclusion System | Atrial Fibrillation | 41 | Jul 2010actual | — | 2013-02-13 |
| AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial FibrillationNCT00560885results2013-03-14Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months.Open-label · Treatment | Phase 3 | Completed | Device: AtriCure Bipolar System | Atrial Fibrillation | 55 | Dec 2009actual | — | 2013-03-29 |
| AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac SurgeryNCT00779857results2013-06-04Rate of Device Related Serious Adverse EventsNon-randomized · Open-label · Treatment | Phase 2 | Completed | Device: AtriCure LAA Exclusion System | Left Atrial Appendage Exclusion | 70 | Oct 2009actual | — | 2013-06-04 |
| Sole-Therapy Treatment of Atrial FibrillationNCT00566176The primary outcome is the feasibility of performing this operation by demonstrating the ability to consistently isolate the right and left PVs using this minimally invasive approach.Non-randomized · Open-label · Treatment | Phase 2 | Unknown status | Device: Surgical Ablation using the AtriCure Bipolar System | Atrial Fibrillation | 25 | Dec 2007actual | — | 2013-02-05 |
| Concomitant Treatment of Permanent Atrial FibrillationNCT00566787Primary efficacy endpoint is the proportion of treated patients who are free of atrial fibrillation without the need for anti-arrhythmic agents at the six-month follow-up visit.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Device: Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System | Atrial Fibrillation | 39 | Dec 2007actual | — | 2012-01-25 |
| AtriCure Minimally Invasive Surgical Ablation for Atrial Fibrillation/RESTORE IIBNCT00571779Feasibility of performing the operation by demonstrating the ability to consistently isolate the left and right pulmonary veins and to confirm conduction block across the roof, anterior and LAA linear lesions. | Phase 2 | Withdrawn | Device: AtriCure Bipolar System | Atrial Fibrillation | — | — | — | 2011-02-21 |
| AtriCure Bipolar Radiofrequency Ablation of Persistent Atrial FibrillationNCT00785902The primary efficacy endpoint for this study is the percent of patients free from AF and off Class I and III antiarrhythmic drugs at 9 months. | Phase 3 | Withdrawn | Device: AtriCure Bipolar System | Atrial Fibrillation | — | — | — | 2011-02-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19